Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from GlaxoSmithKline ( (GSK) ).
On August 28, 2025, GSK plc announced the purchase of 236,167 of its own ordinary shares at prices ranging from 1,460.50p to 1,479.00p per share, as part of its ongoing buyback program initiated on June 4, 2025. This transaction, executed through Merrill Lynch International, increases the total number of shares held in treasury to 244,155,883, representing 6.00% of the voting rights, and reflects GSK’s strategy to manage its capital structure effectively.
The most recent analyst rating on (GSK) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Outperform.
GSK’s overall stock score is driven by strong earnings performance and positive technical indicators. The company’s robust financial health and strategic focus on high-growth segments provide a solid foundation for future growth. Valuation metrics are favorable, and the positive sentiment from the earnings call further supports the stock’s outlook.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK plc, also known as GlaxoSmithKline, is a global healthcare company based in London, primarily involved in the development and production of pharmaceuticals, vaccines, and consumer healthcare products.
Average Trading Volume: 4,860,872
Technical Sentiment Signal: Strong Buy
Current Market Cap: $79.38B
For an in-depth examination of GSK stock, go to TipRanks’ Overview page.